메뉴 건너뛰기




Volumn 44, Issue 8, 2000, Pages 2093-2099

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEIN PRECURSOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

EID: 0033931167     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2093-2099.2000     Document Type: Article
Times cited : (194)

References (43)
  • 2
    • 0029891663 scopus 로고    scopus 로고
    • Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease
    • Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
    • (1996) Antimicrob. Agents Chemother. , vol.40 , pp. 1491-1497
    • Bilello, J.A.1    Bilello, P.A.2    Stellrecht, K.3    Leonard, J.4    Norbeck, D.W.5    Kempf, D.J.6    Robins, T.7    Drusano, G.L.8
  • 3
    • 0031724008 scopus 로고    scopus 로고
    • Resistance to human immunodeficiency virus type 1 protease inhibitors
    • Boden, D., and M. Markowitz. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:2775-2783.
    • (1998) Antimicrob. Agents Chemother. , vol.42 , pp. 2775-2783
    • Boden, D.1    Markowitz, M.2
  • 6
    • 0030671536 scopus 로고    scopus 로고
    • In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates
    • Chong, K.-T., and P. J. Pagano. 1997. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. 41:2367-2373.
    • (1997) Antimicrob. Agents Chemother. , vol.41 , pp. 2367-2373
    • Chong, K.-T.1    Pagano, P.J.2
  • 7
    • 0021118703 scopus 로고
    • Quantitative analysis of dose effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • Chou, T.-C, and P. Talalay. 1984. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
    • (1984) Adv. Enzyme Regul. , vol.22 , pp. 27-55
    • Chou, T.-C.1    Talalay, P.2
  • 12
    • 0032580479 scopus 로고    scopus 로고
    • HIV-protease inhibitors
    • Flexner, D. 1998. HIV-protease inhibitors. Drug Ther. 338:1281-1292.
    • (1998) Drug Ther. , vol.338 , pp. 1281-1292
    • Flexner, D.1
  • 13
    • 0030753305 scopus 로고    scopus 로고
    • Current antiretroviral therapy: An overview
    • Gulick, R. M. 1997. Current antiretroviral therapy: an overview. Quality Life Res. 6:471-474.
    • (1997) Quality Life Res. , vol.6 , pp. 471-474
    • Gulick, R.M.1
  • 15
    • 0003415622 scopus 로고
    • Kendall/Hunt Publishing Co., Dubuque, Iowa
    • Hubert, J. J. 1992. Bioassay. Kendall/Hunt Publishing Co., Dubuque, Iowa.
    • (1992) Bioassay
    • Hubert, J.J.1
  • 16
    • 0026325601 scopus 로고
    • Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S
    • Ido, E., H, Han, F. J. Kezdy, and J. Tang. 1991. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J. Biol. Chem. 266:24359-24366.
    • (1991) J. Biol. Chem. , vol.266 , pp. 24359-24366
    • Ido, E.1    Han, H.2    Kezdy, F.J.3    Tang, J.4
  • 17
    • 0002051756 scopus 로고
    • Infectivity assay (virus yield assay)
    • A. Aldovini and B. D. Walker (ed.). Stockton Press, New York, N.Y.
    • Johnson, V. A., and R. E. Byington. 1990. Infectivity assay (virus yield assay), p. 71-76. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
    • (1990) Techniques in HIV Research , pp. 71-76
    • Johnson, V.A.1    Byington, R.E.2
  • 18
    • 0028231995 scopus 로고
    • Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins
    • Kageyama, S., B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora, and H. Mitsuya. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1107-1111.
    • (1994) Antimicrob. Agents Chemother. , vol.38 , pp. 1107-1111
    • Kageyama, S.1    Anderson, B.D.2    Hoesterey, B.L.3    Hayashi, H.4    Kiso, Y.5    Flora, K.P.6    Mitsuya, H.7
  • 23
    • 0026051925 scopus 로고
    • Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles
    • Kohl, N. E., R. E. Diehl, E. Rands, L. J. Davis, M. G. Hanobik, B. Wolanski, and R. A. Dixon. 1991. Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J. Virol. 65:3007-3014.
    • (1991) J. Virol. , vol.65 , pp. 3007-3014
    • Kohl, N.E.1    Diehl, R.E.2    Rands, E.3    Davis, L.J.4    Hanobik, M.G.5    Wolanski, B.6    Dixon, R.A.7
  • 25
    • 0031466883 scopus 로고    scopus 로고
    • HIV resistance to current therapies
    • Kuritzkes, D. R. 1997. HIV resistance to current therapies. Antiviral Ther. 2:61-67.
    • (1997) Antiviral Ther. , vol.2 , pp. 61-67
    • Kuritzkes, D.R.1
  • 28
    • 0028877042 scopus 로고    scopus 로고
    • Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
    • Livingston, D. J., S. Pazhanisamy, D. J. T. Porter, J. A. Partaledis, R. D. Tung, and G. R. Painter. 1998. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245.
    • (1998) J. Infect. Dis. , vol.172 , pp. 1238-1245
    • Livingston, D.J.1    Pazhanisamy, S.2    Porter, D.J.T.3    Partaledis, J.A.4    Tung, R.D.5    Painter, G.R.6
  • 29
    • 0025099455 scopus 로고
    • Novel fluorogenic substrates for assaying retroviral protease by resonance energy transfer
    • Matayoshi, E. D., G. T. Wang, G. A. Krafft, and J. Erickson. 1990. Novel fluorogenic substrates for assaying retroviral protease by resonance energy transfer. Science 247:954-958.
    • (1990) Science , vol.247 , pp. 954-958
    • Matayoshi, E.D.1    Wang, G.T.2    Krafft, G.A.3    Erickson, J.4
  • 30
    • 0032128592 scopus 로고    scopus 로고
    • Recent developments in HIV protease inhibitor therapy
    • Molla, A., G. R. Granneman, E. Sun, and D. J. Kempf. 1998. Recent developments in HIV protease inhibitor therapy. Antiviral Res. 39:1-23.
    • (1998) Antiviral Res. , vol.39 , pp. 1-23
    • Molla, A.1    Granneman, G.R.2    Sun, E.3    Kempf, D.J.4
  • 33
    • 0030812875 scopus 로고    scopus 로고
    • Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro
    • Patick, A. K., T. J. Boritzki, and L. A. Bloom. 1997. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:2159-2164.
    • (1997) Antimicrob. Agents Chemother. , vol.41 , pp. 2159-2164
    • Patick, A.K.1    Boritzki, T.J.2    Bloom, L.A.3
  • 35
    • 0003007227 scopus 로고
    • "Mini" reverse transcriptase (RT) assay
    • A. Aldovini and B. D. Walker (ed.), Stockton Press, New York, N.Y.
    • Potts, B. J. 1990. "Mini" reverse transcriptase (RT) assay, p. 103-106. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research, Stockton Press, New York, N.Y.
    • (1990) Techniques in HIV Research , pp. 103-106
    • Potts, B.J.1
  • 37
    • 0027416573 scopus 로고
    • Strategic design and three-dimensional analysis of antiviral drug combinations
    • Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
    • (1993) Antimicrob. Agents Chemother. , vol.37 , pp. 540-545
    • Prichard, M.N.1    Prichard, L.E.2    Shipman C., Jr.3
  • 40
    • 0030849517 scopus 로고    scopus 로고
    • Clinically effective HIV-1 protease inhibitors
    • Vacca, J. P., and J. H. Condra. 1997. Clinically effective HIV-1 protease inhibitors. Drug Discov. Today 2:261-272.
    • (1997) Drug Discov. Today , vol.2 , pp. 261-272
    • Vacca, J.P.1    Condra, J.H.2
  • 42
    • 0024578841 scopus 로고
    • New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
    • Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
    • (1989) J. Natl. Cancer Inst. , vol.81 , pp. 577-586
    • Weislow, O.S.1    Kiser, R.2    Fine, D.L.3    Bader, J.4    Shoemaker, R.H.5    Boyd, M.R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.